Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine

摘要

Lucemyra? (lofexidine hydrochloride) has recentlybeen approved by the US FDA for the mitigation of withdrawal symptoms tofacilitate abrupt discontinuation of opioids in adults. Lofexidine is analpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidinediffer in advantageous ways from the classical alpha-2 adrenoceptor agonistclonidine. In the present study, we measured the receptor binding profile oflofexidine and clonidine in an effort to gain an insight into the clinicaldifference(s).